These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 16543686)
1. Is ACEI superior to ARB for CKD? Imai E Intern Med; 2006; 45(4):179-81. PubMed ID: 16543686 [No Abstract] [Full Text] [Related]
2. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Hilgers KF; Dötsch J; Rascher W; Mann JF Pediatr Nephrol; 2004 Sep; 19(9):956-61. PubMed ID: 15278690 [TBL] [Abstract][Full Text] [Related]
3. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270 [TBL] [Abstract][Full Text] [Related]
4. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Shoda J; Kanno Y; Suzuki H Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688 [TBL] [Abstract][Full Text] [Related]
5. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease. Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613 [TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415 [TBL] [Abstract][Full Text] [Related]
7. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Litwin M; Grenda R; Sladowska J; Antoniewicz J Pediatr Nephrol; 2006 Nov; 21(11):1716-22. PubMed ID: 16909244 [TBL] [Abstract][Full Text] [Related]
9. Diabetic kidney disease: an ACEI (or an ARB) in the hole. Yee J Adv Chronic Kidney Dis; 2014 May; 21(3):251-5. PubMed ID: 24780451 [No Abstract] [Full Text] [Related]
10. Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results. Griffin KA; Bidani AK Hypertension; 2009 Jan; 53(1):e3; author reply e4. PubMed ID: 19047576 [No Abstract] [Full Text] [Related]
11. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome. Zhang Y; Wang F; Ding J; Zhang H; Liu X; Wang S; Xiao H; Yao Y; Liu J; Zhong X; Guan N; Su B; Wu G; Yu L Pediatr Nephrol; 2016 Jan; 31(1):67-72. PubMed ID: 26248473 [TBL] [Abstract][Full Text] [Related]
13. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. Miao L; Chen W; Zhou L; Wan H; Gao B; Feng Y Sci Rep; 2016 Feb; 6():21359. PubMed ID: 26883083 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311 [TBL] [Abstract][Full Text] [Related]
16. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Han SW; Won YW; Yi JH; Kim HJ Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126 [TBL] [Abstract][Full Text] [Related]
17. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD. Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415 [TBL] [Abstract][Full Text] [Related]
18. [Current and future medical therapies for CKD (chronic kidney disease)]. Maruyama S Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):166-72. PubMed ID: 18787299 [No Abstract] [Full Text] [Related]
19. [Prevention of CVD in patients with CKD]. Nishimoto-Hazuku A; Node K Nihon Rinsho; 2008 Sep; 66(9):1741-5. PubMed ID: 18788404 [TBL] [Abstract][Full Text] [Related]
20. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]